Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine.
A novel approach is described for the treatment of IgE-mediated allergic reactions which is based on the induction of a strong anti-IgE response in the host. Vaccination of ovalbumin-sensitized rats with constant domains two and three of rat IgE coupled to a heterologous carrier protein resulted in a profound decrease in serum levels of IgE, and later in a nearly complete block of histamine release from mast cells and basophils upon challenge with either a cross-linking polyclonal anti-IgE antiserum or a specific allergen.
Hellman
L
L
Department of Immunology, University of Uppsal, Sweden.
D000485:Allergens / Q000276:immunology*; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D006967:Hypersensitivity / Q000628:therapy*; D007073:Immunoglobulin E / Q000276:immunology*; D007128:Immunoglobulin Fragments / Q000276:immunology; D007167:Immunotherapy; D007958:Leukocyte Count; D008407:Mast Cells / Q000166:cytology; D051381:Rats; D011919:Rats, Inbred Strains; D011993:Recombinant Fusion Proteins / Q000276:immunology; D012882:Skin Tests; D014614:Vaccines, Synthetic / Q000276:immunology*
D000485:Allergens; D000888:Antibodies, Anti-Idiotypic; D007128:Immunoglobulin Fragments; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; D007073:Immunoglobulin E